Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Jonathan L., Mina, Roberto, Jakubowiak, Andrzej J., Zimmerman, Todd L., Wolf, Jeffrey J., Lewis, Colleen, Gleason, Charise, Sharp, Cathy, Martin, Thomas, Heffner, Leonard T., Nooka, Ajay K., Harvey, R. Donald, Lonial, Sagar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320362/
https://www.ncbi.nlm.nih.gov/pubmed/30610196
http://dx.doi.org/10.1038/s41408-018-0154-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320362/
https://www.ncbi.nlm.nih.gov/pubmed/30610196
http://dx.doi.org/10.1038/s41408-018-0154-8

Ejemplares similares